Neuroprotective effect of the carnosine - [alpha]-lipoic acid nanomicellar complex in a model of early-stage Parkinson's disease.
Kulikova, Olga I. a, c, *; Berezhnoy, Daniil S. a, b; Stvolinsky, Sergey L. a; Lopachev, Alexander V. a; Orlova, Valentina S. c; Fedorova, Tatiana N. a
[Article] Regulatory Toxicology and Pharmacology. 95:254-259, June 2018.

(Format: HTML, PDF)

In a model of early-stage Parkinson's disease induced by a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to Wistar rats, a neuroprotective effect of a new derivative of carnosine and [alpha]-lipoic acid (C/LA nanomicellar complex) was demonstrated. Acute intraperitoneal administration of carnosine, [alpha]-lipoic acid and C/LA complex following MPTP administration normalized the total antioxidant activity in the brain tissue. Of all the compounds tested only C/LA complex normalized the metabolism of dopamine (DA) and serotonin (5-HT), while its components did not show similar effects when used separately. C/LA complex effectively restored the level of DA metabolites: the level of DOPAC was increased by 24.7 /- 5.6% compared to the animals that had received MPTP only, and the level of HVA was restored to the values observed in the intact animals. Integral metabolic indices of DA (DOPAC/DA and HVA/DA ratios) and 5-HT turnover (5-HIAA/5-HT ratio) in the striatum tended to increase in case of C/LA complex administration.

Highlights:

* All tested compounds normalized antioxidant status following MPTP administration.

* C/LA complex restored the level of dopamine metabolites: DOPAC and HVA.

* C/LA complex tend to increase DOPAC/DA, HVA/DA and 5-HIAA/5-HT ratios.

(C) 2018Elsevier, Inc.